Marina Cuchel, Eric Bruckert, Henry N Ginsberg, Frederick J Raal, Raul D Santos, Robert A Hegele, Jan Albert Kuivenhoven, Børge G Nordestgaard, Olivier S Descamps, Elisabeth Steinhagen-Thiessen, Anne Tybjærg-Hansen, Gerald F Watts, Maurizio Averna, Catherine Boileau, Jan Borén, Alberico L Catapano, Joep C Defesche, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Luis Masana, Päivi Pajukanta, Klaus G Parhofer, Kausik K Ray, Anton F H Stalenhoef, Erik Stroes, Marja-Riitta Taskinen, Albert Wiegman, Olov Wiklund, M John Chapman
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH...
August 21, 2014: European Heart Journal